Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury

Ferreira-Silva, Margarida; Faria-Silva, Catarina; Baptista, Pedro V.; Fernandes, Eduarda; Fernandes, Alexandra R.; Corvo, M. Luísa

doi:10.1007/s13346-021-00915-8

Cited by 10 publications

(7 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, appropriate comparison is hindered due to two main factors: (i) the selected in vivo model, which differs among laboratories; and (ii) the parameters analyzed to evaluate the therapeutic effect, with distinct combination of techniques being used in each study. Further details about the difficulty in performing comparisons between distinct hepatic IRI treatments can be consulted in Ferreira-Silva et al [4]. There have not been many reports on the use of nanosystems for the delivery of compounds in hepatic IRI (see [4] and references therein).…”

Section: In Vivo Studiesmentioning

confidence: 99%

“…Further details about the difficulty in performing comparisons between distinct hepatic IRI treatments can be consulted in Ferreira-Silva et al [4]. There have not been many reports on the use of nanosystems for the delivery of compounds in hepatic IRI (see [4] and references therein). In fact, a survey of the literature highlights a SOD-containing liposome as the most comparable approach.…”

Section: In Vivo Studiesmentioning

confidence: 99%

“…A quercetin liposomal formulation was previously evaluated for the treatment of other types of acute liver injuries [4]. In that study, a therapeutic effect was observed in transaminases levels and histological parameters.…”

Section: In Vivo Studiesmentioning

confidence: 99%

“…Ischemia and reperfusion injury (IRI) is a common complication, capable of hindering the success of the growing number of liver surgeries [1] due to the development of oxidative stress and inflammation [2,3]. The current therapy for liver IRI includes non-steroid antiinflammatory drugs (NSAID) and corticosteroids that do not achieve the desirable efficacy and additionally can present severe side effects [4]. Therefore, novel and more effective therapeutic approaches are needed.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives are necessary. Drug delivery nanosystems have been explored due to their capacity to improve the therapeutic index of conventional drugs. Within nanocarriers, liposomes are one of the most successful, with several formulations currently in the market. As improved therapeutic outcomes have been demonstrated by using liposomes as drug carriers, this nanosystem was used to deliver quercetin, a flavonoid with anti-inflammatory and antioxidant properties, in hepatic IRI treatment. In the present work, a stable quercetin liposomal formulation was developed and characterized. Additionally, an in vitro model of ischemia and reperfusion was developed with a hypoxia chamber, where the anti-inflammatory potential of liposomal quercetin was evaluated, revealing the downregulation of pro-inflammatory markers. The anti-inflammatory effect of quercetin liposomes was also assessed in vivo in a rat model of hepatic IRI, in which a decrease in inflammation markers and enhanced recovery were observed. These results demonstrate that quercetin liposomes may provide a significant tool for addressing the current bottlenecks in hepatic IRI treatment.

show abstract

Section: In Vivo Studiesmentioning

confidence: 99%

Section: In Vivo Studiesmentioning

confidence: 99%

Section: In Vivo Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ischemia–reperfusion injury also occurs in livers subject to haemorrhagic shock [ 73 ]. Thus, strategies to reduce liver ischemia–reperfusion injury would greatly expand the pool of usable donor livers and hence the survival and wellbeing of patients with end-stage liver disease [ 11 , 72 , 74 ].…”

Section: Trpm2 Channels May Be Involved In Liver Injury Initiated By Ischemia–reperfusion During Liver Surgerymentioning

confidence: 99%

TRPM2 Non-Selective Cation Channels in Liver Injury Mediated by Reactive Oxygen Species

2021

View full text Add to dashboard Cite

TRPM2 channels admit Ca2+ and Na+ across the plasma membrane and release Ca2+ and Zn2+ from lysosomes. Channel activation is initiated by reactive oxygen species (ROS), leading to a subsequent increase in ADP-ribose and the binding of ADP-ribose to an allosteric site in the cytosolic NUDT9 homology domain. In many animal cell types, Ca2+ entry via TRPM2 channels mediates ROS-initiated cell injury and death. The aim of this review is to summarise the current knowledge of the roles of TRPM2 and Ca2+ in the initiation and progression of chronic liver diseases and acute liver injury. Studies to date provide evidence that TRPM2-mediated Ca2+ entry contributes to drug-induced liver toxicity, ischemia–reperfusion injury, and the progression of non-alcoholic fatty liver disease to cirrhosis, fibrosis, and hepatocellular carcinoma. Of particular current interest are the steps involved in the activation of TRPM2 in hepatocytes following an increase in ROS, the downstream pathways activated by the resultant increase in intracellular Ca2+, and the chronology of these events. An apparent contradiction exists between these roles of TRPM2 and the role identified for ROS-activated TRPM2 in heart muscle and in some other cell types in promoting Ca2+-activated mitochondrial ATP synthesis and cell survival. Inhibition of TRPM2 by curcumin and other “natural” compounds offers an attractive strategy for inhibiting ROS-induced liver cell injury. In conclusion, while it has been established that ROS-initiated activation of TRPM2 contributes to both acute and chronic liver injury, considerable further research is needed to elucidate the mechanisms involved, and the conditions under which pharmacological inhibition of TRPM2 can be an effective clinical strategy to reduce ROS-initiated liver injury.

show abstract

Nanoplatform‐Based Reactive Oxygen Species Scavengers for Therapy of Ischemia‐Reperfusion Injury

Wan

et al. 2022

Advanced Therapeutics

View full text Add to dashboard Cite

Ischemia‐reperfusion is a characteristic disorder of many diseases, such as myocardial infarction, stroke, and peripheral vascular diseases. Ischemia‐reperfusion injury (IRI) is one of the most frequent causes of debilitating diseases and death. Relieving organ damage caused by IRI is valuable in safeguarding human life and health. In recent years, nanoplatform‐based reactive oxygen species (ROS) scavengers have attracted widespread attention for alleviation of IRI. To highlight these achievements and to provide a quick perspective for researchers to understand the current research status, recent progress in nanoplatform‐based ROS scavengers for IRI therapy is summarized in this review. This review first summarizes information on the main sites and mechanisms of IRI. Thereafter, this review briefly summarizes and discusses the principles of design, fabrication, and administration of nanoplatform‐based ROS scavengers. Furthermore, the application of nanoplatform‐based ROS scavengers in the treatment of IRI in a variety of organs is also reviewed. Finally, limitations and possible breakthrough in developing ROS scavengers in the field of IRI are discussed. It is hoped that this review will be helpful and enlightening to researcher in medicine, pharmacy, biology, chemistry, and materials science.

show abstract

Drug delivery nanosystems targeted to hepatic ischemia and reperfusion injury

Cited by 10 publications

References 153 publications

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment

Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment

TRPM2 Non-Selective Cation Channels in Liver Injury Mediated by Reactive Oxygen Species

Nanoplatform‐Based Reactive Oxygen Species Scavengers for Therapy of Ischemia‐Reperfusion Injury

Contact Info

Product

Resources

About